“CD30”的意思、由来-开放百科全书

CD30, also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker.

Function

This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. It is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.^[1]

Clinical significance

CD30 is associated with anaplastic large cell lymphoma. It is expressed in embryonal carcinoma but not in seminoma and is thus a useful marker in distinguishing between these germ cell tumors.^[2] CD30 and CD15 are also expressed on Reed-Sternberg cells typical for Hodgkin's lymphoma.^[3]

Cancer treatment

CD30 is the target of the FDA approved therapeutic brentuximab vedotin (Adcetris). It is approved for use in:

Brentuximab vedotin is also currently being studied in and recommended for treating:

Interactions

References

1. ^{{cite web | title = Entrez Gene: TNFRSF8 tumor necrosis factor receptor superfamily, member 8| url = https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=943| accessdate = }}
2. ^{{cite journal | vauthors = Teng LH, Lu DH, Xu QZ, Fu YJ, Yang H, He ZL | title = [Expression and diagnostic significance of OCT4, CD117 and CD30 in germ cell tumors] | language = Chinese | journal = Zhonghua Bing Li Xue Za Zhi Chinese Journal of Pathology | volume = 34 | issue = 11 | pages = 711–5 | date = Nov 2005 | pmid = 16536313 | doi = }}
3. ^{{cite journal | vauthors = Gorczyca W, Tsang P, Liu Z, Wu CD, Dong HY, Goldstein M, Cohen P, Gangi M, Weisberger J | title = CD30-positive T-cell lymphomas co-expressing CD15: an immunohistochemical analysis | journal = International Journal of Oncology | volume = 22 | issue = 2 | pages = 319–24 | date = Feb 2003 | pmid = 12527929 | doi = 10.3892/ijo.22.2.319 }}
4. ^{{cite journal | vauthors = Deng C, Pan B, O'Connor OA | title = Brentuximab vedotin | journal = Clinical Cancer Research | volume = 19 | issue = 1 | pages = 22–7 | date = Jan 2013 | pmid = 23155186 | doi = 10.1158/1078-0432.CCR-12-0290 }}
5. ^{{cite web | url = https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm584543.htm | title = FDA approves Brentuximab vedotin for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma | website = FDA.gov | access-date = March 2, 2018}}
6. ^{{cite journal | vauthors = Berger GK, McBride A, Lawson S, Royball K, Yun S, Gee K, Bin Riaz I, Saleh AA, Puvvada S, Anwer F | title = Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review | journal = Critical Reviews in Oncology/hematology | volume = 109 | issue = | pages = 42–50 | date = January 2017 | pmid = 28010897 | pmc = 5218629 | doi = 10.1016/j.critrevonc.2016.11.009 | url = }}
7. ^{{cite journal | vauthors = Scott LJ | title = Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma | journal = Drugs | volume = 77 | issue = 4 | pages = 435–445 | date = March 2017 | pmid = 28190142 | doi = 10.1007/s40265-017-0705-5 | url = }}
8. ^{{cite journal | vauthors = Hu B, Oki Y | title = Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma | journal = Frontiers in Oncology | volume = 8 | issue = | pages = 139 | date = 2018 | pmid = 29761078 | pmc = 5937056 | doi = 10.3389/fonc.2018.00139 | url = }}
9. ^¹{{cite journal | vauthors = Aizawa S, Nakano H, Ishida T, Horie R, Nagai M, Ito K, Yagita H, Okumura K, Inoue J, Watanabe T | title = Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation | journal = The Journal of Biological Chemistry | volume = 272 | issue = 4 | pages = 2042–5 | date = Jan 1997 | pmid = 8999898 | doi = 10.1074/jbc.272.4.2042 }}

Further reading

{{cite journal | vauthors = Schneider C, Hübinger G | title = Pleiotropic signal transduction mediated by human CD30: a member of the tumor necrosis factor receptor (TNFR) family | journal = Leukemia & Lymphoma | volume = 43 | issue = 7 | pages = 1355–66 | date = Jul 2002 | pmid = 12389614 | doi = 10.1080/10428190290033288 }}

{{cite journal | vauthors = Horie R, Higashihara M, Watanabe T | title = Hodgkin's lymphoma and CD30 signal transduction | journal = International Journal of Hematology | volume = 77 | issue = 1 | pages = 37–47 | date = Jan 2003 | pmid = 12568298 | doi = 10.1007/BF02982601 }}

{{cite journal | vauthors = Tarkowski M | title = Expression and a role of CD30 in regulation of T-cell activity | journal = Current Opinion in Hematology | volume = 10 | issue = 4 | pages = 267–71 | date = Jul 2003 | pmid = 12799531 | doi = 10.1097/00062752-200307000-00003 }}

{{cite journal | vauthors = Granados S, Hwang ST | title = Roles for CD30 in the biology and treatment of CD30 lymphoproliferative diseases | journal = The Journal of Investigative Dermatology | volume = 122 | issue = 6 | pages = 1345–7 | date = Jun 2004 | pmid = 15175022 | doi = 10.1111/j.0022-202X.2004.22616.x }}

{{cite journal | vauthors = Dürkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H | title = Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease | journal = Cell | volume = 68 | issue = 3 | pages = 421–7 | date = Feb 1992 | pmid = 1310894 | doi = 10.1016/0092-8674(92)90180-K }}

{{cite journal | vauthors = Fonatsch C, Latza U, Dürkop H, Rieder H, Stein H | title = Assignment of the human CD30 (Ki-1) gene to 1p36 | journal = Genomics | volume = 14 | issue = 3 | pages = 825–6 | date = Nov 1992 | pmid = 1330892 | doi = 10.1016/S0888-7543(05)80203-4 }}

{{cite journal | vauthors = Josimovic-Alasevic O, Dürkop H, Schwarting R, Backé E, Stein H, Diamantstein T | title = Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay | journal = European Journal of Immunology | volume = 19 | issue = 1 | pages = 157–62 | date = Jan 1989 | pmid = 2537734 | doi = 10.1002/eji.1830190125 }}

{{cite journal | vauthors = Stein H, Gerdes J, Schwab U, Lemke H, Mason DY, Ziegler A, Schienle W, Diehl V | title = Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population | journal = International Journal of Cancer | volume = 30 | issue = 4 | pages = 445–59 | date = Oct 1982 | pmid = 6754630 | doi = 10.1002/ijc.2910300411 }}

{{cite journal | vauthors = Jung W, Krueger S, Renner C, Gause A, Sahin U, Trümper L, Pfreundschuh M | title = Opposite effects of the CD30 ligand are not due to CD30 mutations: results from cDNA cloning and sequence comparison of the CD30 antigen from different sources | journal = Molecular Immunology | volume = 31 | issue = 17 | pages = 1329–34 | date = Dec 1994 | pmid = 7527901 | doi = 10.1016/0161-5890(94)90051-5 }}

{{cite journal | vauthors = Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, Mori S | title = Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3 | journal = Oncogene | volume = 9 | issue = 6 | pages = 1567–74 | date = Jun 1994 | pmid = 8183550 | doi = }}

{{cite journal | vauthors = Lee SY, Park CG, Choi Y | title = T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors | journal = The Journal of Experimental Medicine | volume = 183 | issue = 2 | pages = 669–74 | date = Feb 1996 | pmid = 8627180 | pmc = 2192463 | doi = 10.1084/jem.183.2.669 }}

{{cite journal | vauthors = Gedrich RW, Gilfillan MC, Duckett CS, Van Dongen JL, Thompson CB | title = CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins | journal = The Journal of Biological Chemistry | volume = 271 | issue = 22 | pages = 12852–8 | date = May 1996 | pmid = 8662842 | doi = 10.1074/jbc.271.22.12852 }}

{{cite journal | vauthors = Horie R, Ito K, Tatewaki M, Nagai M, Aizawa S, Higashihara M, Ishida T, Inoue J, Takizawa H, Watanabe T | title = A variant CD30 protein lacking extracellular and transmembrane domains is induced in HL-60 by tetradecanoylphorbol acetate and is expressed in alveolar macrophages | journal = Blood | volume = 88 | issue = 7 | pages = 2422–32 | date = Oct 1996 | pmid = 8839832 | doi = }}

{{cite journal | vauthors = Aizawa S, Nakano H, Ishida T, Horie R, Nagai M, Ito K, Yagita H, Okumura K, Inoue J, Watanabe T | title = Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation | journal = The Journal of Biological Chemistry | volume = 272 | issue = 4 | pages = 2042–5 | date = Jan 1997 | pmid = 8999898 | doi = 10.1074/jbc.272.4.2042 }}

{{cite journal | vauthors = Lee SY, Lee SY, Choi Y | title = TRAF-interacting protein (TRIP): a novel component of the tumor necrosis factor receptor (TNFR)- and CD30-TRAF signaling complexes that inhibits TRAF2-mediated NF-kappaB activation | journal = The Journal of Experimental Medicine | volume = 185 | issue = 7 | pages = 1275–85 | date = Apr 1997 | pmid = 9104814 | pmc = 2196258 | doi = 10.1084/jem.185.7.1275 }}

{{cite journal | vauthors = Boucher LM, Marengère LE, Lu Y, Thukral S, Mak TW | title = Binding sites of cytoplasmic effectors TRAF1, 2, and 3 on CD30 and other members of the TNF receptor superfamily | journal = Biochemical and Biophysical Research Communications | volume = 233 | issue = 3 | pages = 592–600 | date = Apr 1997 | pmid = 9168896 | doi = 10.1006/bbrc.1997.6509 }}

{{cite journal | vauthors = Duckett CS, Thompson CB | title = CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival | journal = Genes & Development | volume = 11 | issue = 21 | pages = 2810–21 | date = Nov 1997 | pmid = 9353251 | pmc = 316646 | doi = 10.1101/gad.11.21.2810 }}

{{cite journal | vauthors = Mizushima S, Fujita M, Ishida T, Azuma S, Kato K, Hirai M, Otsuka M, Yamamoto T, Inoue J | title = Cloning and characterization of a cDNA encoding the human homolog of tumor necrosis factor receptor-associated factor 5 (TRAF5) | journal = Gene | volume = 207 | issue = 2 | pages = 135–40 | date = Jan 1998 | pmid = 9511754 | doi = 10.1016/S0378-1119(97)00616-1 }}